Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023241 (Legionella)
 6,990 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

An antigen prepared with agar-grown Legionella pneumophila group 1 killed by 0.5% phenol and suspended in 0.5% yolk sac was examined for use in the indirect immunofluorescence test for legionellosis and compared with a heat-killed antigen. The serological results of the two antigens for single and paired sera agreed well. Morphological and staining characteristics were better for phenol-treated organisms. Electron microscopy observation showed an apparently well-preserved cell surface. The background antibody level among a healthy control population was very low (3.4% with titers of greater than or equal to 16). Sera of patients with gram-negative bacteria infections (Yersinia enterocolytica, Campylobacter jejuni, Salmonella typhimurium, Escherichia coli, Brucella melitensis, Pseudomonas aeruginosa, Mycoplasma pneumoniae, Coxiella burnetti, and Chlamydia psittaci) showed no cross-reactions with the phenol-killed antigen. The data suggest that phenol-killed antigen is sensitive and specific. This antigen is stable for at least 1 year.
 ...
PMID:Comparison of phenol- and heat-killed antigens in the indirect immunofluorescence test for serodiagnosis of Legionella pneumophila group 1 infections. 638 81

A previously well 56 year-old woman presented with an adult respiratory distress syndrome which worsened under penicillin treatment, responding only to erythromycin and rifampicin, as well as CPAP ventilation. Diagnostic serology was positive to Chlamydia psittaci. Psittacosis is not a frequent cause of primary extensive pneumonia in intensive care units; other diseases should be looked for in the presence of these non-specific clinical and biological pictures (Legionella pneumophila, Mycoplasma pneumoniae, Streptococcus pneumoniae). Pneumocystis should also be looked for in a typical pneumonia; erythromycin is the antibiotic of first choice in the treatment of primary extensive pneumonia.
 ...
PMID:[Severe Chlamydia psittaci pneumopathy in an adult]. 639 29

Because of the possible serological cross reactions frequently described in the literature between L. pneumophila and M. pneumoniae or between L. pneumophila and Chlamydia, we decided to determine their frequency with our sera and our own methods. The anti M. pneumoniae and Chlamydia antibodies were researched in 162 sera samples from 46 cases of legionellosis serologically diagnosed and in 51 sera from 26 hyperimmunised rabbits. Conversely, anti L. pneumophila antibodies were researched in 165 sera from mycoplasmosis (61) or chlamydiosis (25 cases). None of the sera from mycoplasmosis or chlamydiosis tested by IFA and MA had antilegionella antibodies. None of the rabbits' sera hyperimmunised with Legionella had anti M. pneumoniae or Chlamydia antibodies. On the contrary, by complement fixation and IFA, out of the 46 cases of legionellosis under study, 6 showed a seroconversion in M. pneumoniae and 2 in Chlamydia. The Ig class determination did not show IgM titers in 7 of these 8 sera. The mechanisms of these cross reactions are discussed: antigens and methods used, booster effect during legionellosis, concurrent mycoplasmosis or chlamydiosis.
 ...
PMID:[Evaluation of the incidence of serological cross reactions between Legionella and Mycoplasma or Chlamydia]. 642 88

From 15 to 21 August 1981, Pontiac fever affected 317 automobile assembly plant workers. Results of serologic tests were negative for Mycoplasma, Chlamydia, respiratory tract viruses, and previously described legionellae. A gram-negative, rod-shaped organism (WO-44C) that did not grow on blood agar, required L-cysteine for growth, and contained large amounts of branched-chain fatty acids was isolated from a water-based coolant. The organism did not react with antisera against other legionellae, and on DNA hybridization the organism was less than 10% related to other Legionella species. Geometric mean titers found by indirect fluorescent antibody testing to WO-44C were significantly higher in ill employees than in controls (p = 0.0001). Attack rates by department decreased linearly with the department's distance from the implicated coolant system. The etiologic agent apparently was a new Legionella species; we propose the name Legionella feeleii species nova (AATC 35072). This is the first outbreak of nonpneumonic legionellosis in which the etiologic agent is not L. pneumophila, serogroup 1.
 ...
PMID:A new Legionella species, Legionella feeleii species nova, causes Pontiac fever in an automobile plant. 669 54

Out of 2,105 patients with atypical pneumonia and febrile infections 15 cases of legionellosis were diagnosed by the indirect immunofluorescent antibody test (IFA) in Austria from the middle of 1977 to the end of 1979. Among the patients with the diagnosis of atypical pneumonia Legionnaires' disease was found in 0.65%. Among those patients whose sera were examined because of suspected legionella infection the frequency was 1.96% (p less than 0.1). Therefore it may assumed that some symptoms of legionella infections may lead to the clinical diagnosis of the disease. Neither the geographical distribution of the cases nor environmental examinations nor the prevalence of antibodies gave any indication of an epidemic or hyperendemic occurrence of Legionnaires' disease in Austria. Low antibody titres to serogroup 1 of Legionella pneumophila (1:32-1:64) were found in 6.4%, higher titres (greater than or equal to 1:128) in 1.2% of all patients examined. Crossreactions of sera mainly occurred between antigens of serogroup 1 and serogroup 2. Antibodies to serogroups 3 and 4 were found seldom. According to our results crossreactivity between L. pneumophila on the one side and Mycoplasma pneumoniae or Chlamydia psittaci on the other side is of no importance and does not interfere with serological diagnosis. In serological routine examinations frequency of recent infections with L. pneumophila in patients with pneumonia was about as high as with Chlamydia psittaci or Picornavirus. To our opinion the expenditure for serological diagnosis is justified in all patients with severe pneumonia of unclear etiology as there exists the possibility of a purposive chemotherapy in legionellosis as it does in mycoplasma pneumonia or ornithosis. Moreover for quick diagnosis it should always be attempted to demonstrate the causative agent by direct immunofluorescence or by isolation.
 ...
PMID:[Epidemiology and diagnosis of Legionella infections in Austria (author's transl)]. 679 7

The tetracyclines are active in vitro against many urinary tract pathogens such as Chlamydia, Mycoplasma pneumoniae, Brucella, rickettsiae, and Nocardia. Chloramphenicol is used primarily for anaerobic infections, Haemophilus influenzae meningitis, and infections due to Salmonella typhi. Erythromycin is active in vitro against M. pneumoniae, Legionella spp., Streptococcus pneumoniae, and group A beta-hemolytic streptococci; it may also be used as prophylactic therapy for subacute bacterial endocarditis and for recurrence of acute rheumatic fever in patients who are allergic to penicillin. Clindamycin should be used primarily for the treatment of anaerobic infections. The tetracyclines may cause gastrointestinal upset; phototoxic dermatitis; hepatitis, especially in pregnant women; discoloration of the teeth and bone dysplasia in the human fetus and in children; and superinfections, especially oral and anogenital candidiasis. The tetracyclines should be used with caution in patients with renal insufficiency. The most important toxic effect of chloramphenicol is bone marrow suppression, which is dose related or idiosyncratic. The incidence of undesirable side effects associated with the use of erythromycin is low; gastrointestinal irritation is the most common, and cholestatic hepatitis may occur with the use of erythromycin estolate. Pseudomembranous colitis is the most important toxic effect associated with the use of clindamycin.
 ...
PMID:Tetracyclines, chloramphenicol, erythromycin, and clindamycin. 682 63

Sera with concurrent rises in titer to Legionella and mycoplasmal or chlamydial antigens were absorbed with whole Legionella organisms. Absorption removed Legionella reactivity only. No evidence of cross-reactivity between Legionella organisms and either Mycoplasma or Chlamydia organisms was found in studies of hyperimmune rabbit antisera.
 ...
PMID:Studies of the specificity of Legionella serology. 709 62

The authors report the first two cases of legionnaires' disease from Catalonia. Both patients were chronic bronchitic males, and the cases were sporadic. The onset of the disease was characterized by a febrile illness with muscle and joint pains, respiratory symptoms (cough and mucous sputum production), and mental changes. There were no digestive complaints. Pulmonary consolidation occurred in both patients in the left upper lobe. Blood chemistries disclosed the existence of an absolute lymphopenia, altered liver function tests, and elevated CPK levels. Bacterial cultures of blood and sputum, respiratory virus screening (influenza A and B, parainfluenza 1, 2 and 3, and adenoviruses), and tests for Mycoplasma pneumoniae, Coxiella burnetti and Chlamydia psittaci were all negative. Antibody titers against Legionella pneumophila by indirect immunofluorescence were 1/1024 (positive) for serotype 1 and 1/1024 (positive) for serotype II in one patient, and 1/1024 (positive) for serotype I and 1/128 (negative) for serotype II in the other patient. The authors review the epidemiological, clinical, biochemical and diagnostic aspects of legionnaires' disease, which knowledge will undoubtedly allow to detect an increasing number of cases.
 ...
PMID:[Legionnaires' disease. First observations in Catalonia (author's transl)]. 725 29

Miocamycin is an orally administered 16-membered macrolide antimicrobial drug. It has a spectrum of in vitro activity similar to that of erythromycin, inhibiting a range of Gram-positive and Gram-negative organisms, atypical microbes and some anaerobes. Importantly, miocamycin demonstrates greater in vitro potency than erythromycin against several pathogens including Legionella pneumophila, Mycoplasma hominis, and Ureaplasma urealyticum. Equally noteworthy is its activity against erythromycin-resistant staphylococcal and streptococcal species expressing inducible-type resistance. Miocamycin possesses poor overall activity against Haemophilus influenzae and is inactive against Enterobacteriaceae. Penetration of miocamycin into body tissues and fluids is both rapid and extensive. The 3 major metabolites of miocamycin possess antimicrobial activity and may contribute to the therapeutic efficacy of the drug. Clinical data indicate that miocamycin is useful in the treatment of upper and lower respiratory tract infections in both adult and paediatric patients. Miocamycin is also effective in the treatment of urogenital tract infections caused by Chlamydia trachomatis or U. urealyticum. Several studies suggest that miocamycin is at least as effective as erythromycin in these indications; however, comparisons with newer macrolide agents have yet to be performed. In other studies, miocamycin proved to be a useful agent in the treatment of periodontal infections and as anti-infective prophylaxis in dental surgery. Miocamycin appears to have a tolerability profile qualitatively similar to that of other macrolides, with gastrointestinal and skin disorders being the most commonly reported adverse events. Current data suggest that the potential for drug interactions with miocamycin is low, with the possible exceptions of carbamazepine and cyclosporin. Thus, although further confirmation and elaboration of various aspects of its efficacy and tolerability profile is needed, at this stage miocamycin offers a useful alternative oral therapy to erythromycin for the treatment of uncomplicated community-acquired respiratory tract infections and nongonococcal urethritis.
 ...
PMID:Miocamycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. 750 53

Quinolones are a class of antibiotics structurally related to nalidixic acid. They exhibit bactericidal activity primarily by inhibiting bacterial DNA gyrase. The early quinolones had a limited spectrum of activity, low potency, high frequency of spontaneous bacterial resistance, low serum drug concentrations and short half-lives, which virtually restricted their use to urinary tract infection. The new fluorinated quinolones differ from their predecessors in their broad antibacterial spectrum, including both Gram-negative and Gram-positive aerobic, and facultative anaerobic bacteria as well as many Mycobacterium spp., Chlamydia spp., Legionella spp. and Mycoplasma spp., in addition to many strains of bacteria that are multiresistant to beta-lactam antibiotics and aminoglycosides. They also exhibit high potency, a low incidence of resistance, high oral bioavailability, extensive tissue penetration, low protein binding and long elimination half-lives. They are generally well tolerated apart from some gastrointestinal disturbance and rashes, including photosensitive eruptions and a propensity to cause central nervous system excitation. Clinically important interactions include those with antacids, theophylline, fenbufen and warfarin. Potential toxic effects include cartilage damage, ocular toxicity, teratogenicity and impairment of spermatogenesis. The role of fluoroquinolones continues to widen, encompassing infections of the urinary tract, respiratory tract, skin and soft tissues, bone and joints, infections in immunocompromised patients, sexually transmitted diseases, infectious diarrhoea, gynaecological infections and surgical prophylaxis. The convenience of oral therapy is an added advantage of the new fluoroquinolones.
 ...
PMID:Quinolone antibacterials. An update of their pharmacology and therapeutic use. 752 29


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>